Two Japanese companies, health tech firm 4H and Ecoliz Pharma, a biopharmaceutical company focused on treating mental health disorders, are collaborating to better understand and help people with sleep disorders.
Their goal is to gain an objective understanding of sleep disorders, particularly narcolepsy and the excessive daytime sleepiness associated with obstructive sleep apnea (OSA). They will use AI and other methods to analyze objective data on sleep, activity, and heart rate collected from wearable devices, as well as subjective sleep assessments of patients.
The partners aim to identify digital biomarkers or symptoms that predict the onset of daytime sleepiness. Their study will also analyze daytime sleep patterns and sleep characteristics and compare the patients’ daytime activity data with those without sleep disorder symptoms.
In the long term, they plan to build a comprehensive sleep ecosystem for patients, including digital sleep biomarkers to predict health risks, improve patient productivity and quality of life. Includes personal data, and home sleep disorder management programs.
Why is this important?
In a press statement, the companies noted how difficult it is to objectively identify sleep disorders and how they rely on patients’ memory and self-reports, which poses a challenge in diagnosing and providing appropriate treatment. stands as
According to research, Japanese people sleep less than other people around the world due to lack of understanding of the importance of sleep. This is why the Japanese government has launched the Health Japan 21 program that seeks to raise awareness about sleep, among other important topics.
Delaying medical intervention and allowing the complications of sleep disorders to develop can lead to increased overall costs to society, including medical care costs, noted Acolis Pharma and FourH.
“It is important to accurately diagnose sleep disorders and provide appropriate medical care at an early stage to improve patient quality of life, prognosis, productivity, and other factors,” he said.
This isn’t the first effort in Japan to try to develop digital therapies to treat sleep disorders. Last year, Japanese IT company SoftBank Corp. An agreement was made with Pear Cure For Japanese people to develop sleep-wake syndrome DTx. The latter has an FDA-approved device for the treatment of chronic insomnia called Summer ricewhich was launched in late 2020.
The following year, the US FDA granted de novo approval for the first therapeutic device for OSA. exciteOSA. This is a tongue muscle stimulator prescription for adults that relieves mild insomnia and snoring.
Meanwhile, new devices that can detect sleep disorders have hit the Asia Pacific market. The start of South Korea Honey naps has launched SOMNUM, its AI-based software that provides automated and accurate polysomnography readings for diagnosing sleep disorders.
last year, BUZUDA medical device brand in Singapore launched a line of smartwatches with sleep apnea detection, among other health monitoring features.
Also, ASX-listed Travel app It recently received US FDA 510(k) clearance for its mobile sleep apnea screening app SleepCheckRx. The prescription-only app analyzes on-screen breathing and snoring sounds for sleep disorder risks.
#updated #partnership #Japan #wearables #study #sleep #disorders